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TolerabilityAbstract Background: Acute otitis media (AOM) is a community-acquired respiratory tract infec-
tion in childhood frequently encountered by primary-care physicians and can cause a significant
morbidity. Increasing bacterial resistance has led to concern about the current options for empirical
antibiotic treatment and has prompted a search for effective treatments.
Objectives: To evaluate the clinical efficacy and safety of cefpodoxime proxetil in the treatment of
children with acute otitis media.
Patients and methods: A prospective, multicenter study was conducted on 1380 children aged from
1 to 13 years with AOM who were prescribed a 5–10 day course of cefpodoxime proxetil (8 mg/kg/
day). Patients were followed-up after 7–14 days from baseline visit. Efficacy was assessed by the
percentage of patients with clinical cure, improvement or failure at the follow-up visit. Safety
was evaluated by recording the occurrence and severity of any adverse events and by the physicians’
and patients’ assessment of overall tolerability.
Results: Clinically, 82.5% of patients were cured, 16.4% improved and there was failure of therapy
in 1.1% of the patients. The overall combined cure and improvement rate of all related signs and
symptoms was 98.9%. Adverse events, diarrhea and skin rash, were reported by only 16 patients
(1.2%). The overall tolerability according to the physicians’ and patients’ assessment was excellent
in 93.9% and 88.9%, respectively. Compliance was attained in 99.5% of patients.
Conclusion: Cefpodoxime proxetil is an effective, safe, well-tolerated antimicrobial agent for treat-
ment of acute otitis media in children. It can be considered as an excellent choice for the empirical
treatment of bacterial AOM.
 2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute otitis media (AOM) is one of the most frequent diseases
in early infancy and childhood. It is defined as the presence of
middle-ear effusion and a rapid onset of signs or symptoms of
middle-ear inflammation, such as ear pain, otorrhea or fever.1
It is estimated that more than two-thirds of children experience
82 M.H. El-Shabrawi et al.one or more attacks of AOM by the age of 3 years.2–4 The
peak age of incidence is 6–24 months and decreases with age.5
The pathogenesis of AOM is multifactorial, involving the
adaptive and native immune system, Eustachian-tube dysfunc-
tion, viral and bacterial load, in addition to genetic and environ-
mental factors.2 Bacteria are believed to play a predominant
role in the causation of AOM-related symptoms; therefore
antibiotic therapy will accelerate the clinical recovery and may
reduce the number of complications related to AOM.4,6
Streptococcus pneumoniae has been reported as the predom-
inant pathogen causing AOM for many years, next toMoraxella
catarrhalis and non-typeableHaemophilus influenzae. The imple-
mentation of vaccination programs for pneumococcal infection
changed the etiology of AOM overtime resulting inH. influenzae
to be the main pathogen in AOM.7,8 Moreover, increasing
bacterial resistance, particularly beta-lactamase producing
strains of H. influenzae and M. catarrhalis as well as penicillin
and macrolide resistance among S. pneumoniae, has raised the
concern about the current options for empirical antibiotic treat-
ment and has prompted a search for effective treatments.1,6,9
Cefpodoxime proxetil is an oral third generation cephalos-
porin of choice for the treatment of AOM.1 It exhibits more bal-
anced spectra of activity against the principal bacterial
pathogens responsible for outpatient respiratory tract and
other infections when compared with other widely used
amoxicillin or oral cephalosporin of earlier generations.10 In
vitro studies show that it has activity against many common
Gram-positive and Gram-negative pathogens associated with
common pediatric infections including AOM, making it a
useful option for empirical therapy.1,6,11 Moreover, in vivo sen-
sitivity studies assessing the bacteriological efficacy by examin-
ing middle-ear fluid before and a few days after the start of
treatment and retrospective analyses of treatment failures, have
shown a good bacteriological efficacy for cefpodoxime against
H. influenzae and penicillin-susceptible S. pneumoniae.7,8 It is
highly stable to hydrolysis by the most commonly found
plasmid-mediated b-lactamases.10 As well, its concentration
within the structures of the middle ear have been shown to
achieve the minimum inhibitory concentration (MIC) for the
microorganisms responsible for AOM with recommended
dosing schedules. Its relatively long half-life and sustained tis-
sue concentrations support twice daily dosing, representing an
advantage over many other antibiotics with comparable clinical
efficacy and features that may encourage patient compliance.11
Non-compliance is a common cause of treatment failure,
clinicians should strongly consider factors that will enhance
compliance, such as palatability, frequency of administration,
adverse events (AEs) and cost. Finally, physicians’ familiarity
with dosing schedules and potential side effects may reduce
prescribing errors.12
The aim of the study was to evaluate the clinical efficacy
and safety of cefpodoxime proxetil in the treatment of children
with acute otitis media.Patients and methods
Study design
This prospective, multicenter study was conducted in 26 Egyptian
medical centers, over a period of one year from January to
December 2013. The study was approved by the local EthicsCommittee. A written informed parental/guardians’ consent
was obtained prior to enrollment in the study.
Study population
A total of 1380 children aged 1–13 years, presenting with clin-
ically diagnosed AOM suspected to be of bacterial origin were
eligible for the study. Patients were not on any antibiotic ther-
apy when enrolled in the study. The exclusion criteria were
restricted to the contraindications to cefpodoxime given in
the summary of the product characteristics, i.e. patients with
known hypersensitivity to cephalosporin antibiotics.
Methods
Study procedure
The study was conducted in 2 visits, baseline visit at clinical
evaluation and treatment initiation, and follow-up visit (day
7–14) following the routine practice of the trained physician.Baseline visit
All candidates were subjected to comprehensive history-taking
and clinical evaluation. The diagnosis of purulent AOM was
based on a triad of recent clinical symptoms including otalgia,
fever and irritability; tympanic membrane (TM) signs of AOM
such as middle ear effusion characterized by bulging, limited or
absent mobility of the TM or air-fluid level behind membrane;
and otoscopic evidence of TM inflammation indicated by
erythema, perforation or otorrhea in at least one ear were
eligible for the study.13 Patients fulfilling the eligibility criteria
were prescribed cefpodoxime proxetil 8 mg/kg/day in two
divided doses for 5–10 days. Additional medications for symptom
relief were prescribed and documented.
Evaluation visit
The physician examined the patient and recorded their adher-
ence to therapy, any drug adverse events and the clinical
response to treatment. Symptoms of otalgia, fever and irri-
tability were assessed and recorded. Otoscopy was performed
to assess the tympanic membrane for severity of erythema,
opacification, loss of light reflex, fullness or bulging, drainage,
perforation, mobility and middle ear effusion. Patients were
also monitored for any complications. Patients were consid-
ered to be compliant with the study medication if at least
80% of the antimicrobial course were taken according to the
prescribed regimen; otherwise the patient was considered to
be non-compliant.
Study endpoints
Primary and secondary endpoints were the efficacy and safety
assessment of cefpodoxime, respectively.
Efficacy assessment
According to the physicians’ assessment, efficacy was defined
by the percentage of patients with either clinical cure: absence
of fever, otalgia, irritability, and otoscopic signs of AOM;
clinical improvement: clinical signs and symptoms including
otoscopic findings diminished but did not completely resolve;
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signs or symptoms of AOM, or worsening of the patients’
condition.
Safety assessment
Safety was monitored by recording the cefpodoxime related-
adverse events (AEs) during the observational period and by
the physicians’ and patients’ assessment of overall tolerability
at the end of the study. The recorded clinical AEs likely to be
related to the use of antibiotics are vomiting, diarrhea or
rash.4,14 The severity was assessed by the physicians as mild,
moderate or severe. Necessary treatment, outcome at time of
report and serious criteria of AEs were recorded. The assess-
ment of the overall tolerability was rated either: excellent, fair
or poor.
Statistical analysis
Data were analyzed using Statistical Package for Social
Sciences software version 17.0 (SPSS, Inc., Chicago, IL,
USA). Numerical data were expressed as mean and standard
deviation. Qualitative data were expressed as frequency and
percentage. Chi-square test was used to examine the relation
between the qualitative variables. p-value <0.05 was consid-
ered statistically significant.
Results
Two patients out of the enrolled 1380 patients did not show up
at the follow-up visit and were excluded. Of the 1378 patients
who completed the study, 788 (57.2%) were males and 590
(42.8%) were females, with a mean age of 3.8 ± 2.5 years.
Their mean weight and length/height measured at the initial
visit were 17.1 ± 7.1 kg and 94.4 ± 19.0 cm respectively.
At baseline visit
The mean temperature was 38.3 ± 0.7 C. All children had
one or more pretreatment AOM related signs and symptoms;
the most frequent were otalgia (93.6%), spontaneous otorrhea
(51%), purulent discharge (49.7%), fever (21.6%) and erythe-
matous tympanic membrane (1.7%). In addition, nasal dis-
charge was found in 3.3% of patients, sore throat in 2.4%,
cough in 2.2%, and pharyngitis in 1.4% (Fig. 1). The onset
of the first symptom occurred at less than 4 days prior to the
baseline visit in 87.9% of the patients.
The most frequently reported prescription durations were
five days in 783 (56.8%), seven days in 326 (23.7%) and ten
days in 269 (19.5%) of the patients, with a mean duration of
6.5 ± 2.0 days. Other symptomatic medications were pre-
scribed in 66.4% of the patients, including: antipyretics
(24.7%), analgesics (22.1%), decongestants (14.6%), cough
preparations (2.2%) and anti-inflammatory agents (8.3%).
At the follow-up visit
There was marked improvement of all AOM-related signs and
symptoms. Seven patients (0.5%) were non-compliant. Among
the remaining 1371 patients – according to physicians’ assess-
ment – 1131 patients (82.5%) were cured, 225 (16.4%)improved, and 15 (1.1%) failed to respond to therapy; with
one reported worsening of patient’s condition. Cure or
improvement rate was 100% in all symptoms and signs except
spontaneous otorrhea (98.0%), purulent discharge (98.5%)
and nasal discharge (93.5%).
Patients that received a 5-day course of cefpodoxime had a
significantly higher cure rate of 84.6% (659/779) compared to
those taking cefpodoxime for a duration of more than 5 days
(472/592, 79.7%) (v2 = 5.515, p= 0.019).
Adverse events of cefpodoxime were reported by only 16
patients (1.2%), which included diarrhea (n= 9) and skin rash
(n= 7). The nature of the AEs were mild to moderate and did
not require any dose reduction or discontinuation of the pre-
scribed course; while none of the AEs reported were serious
and all resolved without sequelae (Table 1).
The overall tolerability of cefpodoxime according to the
physicians’ assessment was excellent in 1287 (93.9%) of
patients, fair in 73 (5.3%) and poor in 11 (0.8%); while accord-
ing to the patients’ assessment, it was excellent in 1219
(88.9%), fair in 142 (10.4%) and poor in 10 (0.7%) (Fig. 2).Discussion
Acute otitis media is a community-acquired respiratory tract
infection, frequently encountered by primary-care physicians.
Most often the bacterial etiology of infection is not confirmed
prior to initiation of treatment, therefore physicians prescrib-
ing empirical antibiotics need to take into account the major
causative bacteria.1,6 The selection of the most effective antimi-
crobial to treat AOM has become more difficult in recent years
because of increasing antibiotic resistance among all AOM
pathogens to the standard first-line recommended antibi-
otics.15,16 This has prompted a search for other safe, effective
antibiotics necessary to achieve good clinical efficacy and help
to prevent the development of resistance.1,4,6,9 Empirical treat-
ment by cephalosporin with beta lactamase stability should
be preferred especially in cases with penicillin allergy. Cefpo-
doxime is one of three oral third generation cephalosporins
recommended for empiric antibiotic treatment of AOM as
designated by the AAP guidelines.1
The current multicenter study was designed to evaluate the
efficacy and safety of cefpodoxime proxetil in the treatment of
bacterial AOM in children. The patients were recruited from
26 centers located in different areas throughout Egypt covering
various communities and socioeconomic classes. Thus, we
believe that it can be a good representative sample of Egyptian
pediatric population.
Findings of this study indicate that cefpodoxime is an effec-
tive antimicrobial agent for AOM. The 5–10 day treatment
course resulted in an excellent response in signs and symptoms.
Clinical cure was achieved in 82.5% of patients; and improve-
ment in 16.4%, with an overall combined cure and improve-
ment rate of 98.9%. The clinical efficacy of cefpodoxime in
this study was found to be in line with earlier clinical studies
for cefpodoxime who found that the overall combined cure
and improvement rate ranged from 86% to 95%.17–19 As well
it is supported by the results of other earlier two trials conclud-
ing that cefpodoxime demonstrated significantly greater
clinical efficacy and cure rates than either cefixime or amoxicil
lin–clavulanate, respectively.18,20
Figure 1 Signs and symptoms of acute otitis media at baseline visit (n= 1378).
Table 1 Cefpodoxime related-adverse events (n= 1371).
Number Percentage
Adverse event
Diarrhea 9 0.7
Skin rash 7 0.5
Severity
Mild 8 0.6
Moderate 8 0.6
Treatment
No 8 0.6
Yes 8 0.6
Outcome at time of report
Resolved 16 1.2
Serious criteria of adverse events
No 16 1.2
Yes 0 0.0
Figure 2 Tolerability assessment from the physicians’ and
patients’ perspectives (n= 1371).
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AOM is uncertain.1 In the present study it was found that
cefpodoxime, in the 5-day treatment regimen, seems to be a
suitable drug for AOM in children, with a significantly highercure rate (84.6%) than an extended treatment course (79.7%)
(p= 0.019).
Regarding safety, cefpodoxime was well tolerated by most
patients. It has a tolerability profile similar to that of other oral
cephalosporins, with gastrointestinal related symptoms and
skin rash being the most frequently reported AEs.21 The nature
of the AEs were mild to moderate and did not require any dose
reduction or discontinuation of the prescribed course; while
none of the AEs reported were serious and all resolved without
sequelae.
The twice daily regimen was acceptable to the majority of
patients and accordingly compliance to treatment regimen
was excellent (99.5%). It has been noted that patient compli-
ance is inversely related to the frequency of drug administra-
tion and is directly related to the efficacy of the drug.22
Moreover, the less frequent dosing schedule of cefpodoxime
(bd) compared with either amoxicillin–clavulanate or cefaclor
(tds), would be an added advantage for treatment with
cefpodoxime.21
As a consequence, the efficacy and safety of cefpodoxime
reported in this multicenter study is likely to be a true reflec-
tion of the effectiveness in actual clinical pediatric practice.Conclusion
Cefpodoxime proxetil is an effective, safe, well-tolerated
antimicrobial agent for treatment of acute otitis media in chil-
dren. It is an excellent choice for the empirical treatment of
bacterial AOM, with a recommended twice-daily regimen for
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